Actinic Keratosis Treatment Market Set to Grow 2X During 2019-2029
Actinic keratosis has been one of the most commonly diagnosed dermatological diseases that continues to create a strong need for efficacious treatments for this condition. In 2019, the global adoption of actinic keratosis treatment will account for over US$ 4.3 Bn, which are further projected for a strong growth, almost twofold, by 2029. With constant advancements in diagnostic techniques for actinic keratosis, the global demand of actinic keratosis treatment will surge at a robust rate in the following years.
Key Factors Shaping Actinic Keratosis Treatment Market
Launch of Pipeline Products for Actinic Keratosis Treatment
Various topical medication options are available for actinic keratosis treatment, which have given dermatologists an upper hand to prescribe appropriate treatment approach. There are currently 39 studies in phase 4 for actinic keratosis treatment under U.S. FDA. These studies involve potential drugs, combination drugs, and up gradation of existing drugs. For instance, Aclaris Therapeutics, Inc. is focusing to get approval for 101-A solution (currently in phase 4), a topical treatment option for actinic keratosis. Hence, new product launches are expected in the coming years as large number of products for approval are in pipeline for actinic keratosis treatment. This is expected to offer competitive advantage to manufacturers in the actinic keratosis treatment market.
Low Treatment Cost and Favorable Reimbursements
Low treatment cost for actinic keratosis along with favorable reimbursements by Medicare and Medicaid are factors expected to boost growth of the market during the forecast period. The cost of topical treatment for actinic keratosis depends on the patient's preference for branded or generic products. For patients with health insurance, out-of-pocket cost of visiting dermatology clinics is around US$ 5 - US$ 30. Cryotherapy is the most common treatment for actinic keratosis that costs around US$ 400, whereas laser therapy can cost around US$ 100-5,000 depending upon the need of the treatment. Medicare also provides different CPT codes for the treatment of actinic keratosis by different methods such as photodynamic therapy and cryotherapy.
Photodynamic Therapy - Successful Treatment Approach for Actinic Keratosis
Photodynamic therapy (PDT) is one of the most successful treatment options for actinic keratosis. Hence, it is mostly prescribed by physicians when topical treatment or Cryotherapy are not effective. Although the success rates for photodynamic therapy are high, it is not cost effective. This is offering other dermatological product manufacturers to launch their products for photodynamic therapy with less cost to upsurge their revenue growth. Currently, Levulan Kerastick by Sun Pharmaceutical, Ameluz by Biofrontera, and Metvix by Galderma are the major products available in the market for photodynamic therapy. These brands are estimated to gain a majority of the market share in the actinic keratosis treatment market.
Actinic Keratosis Treatment Market Structure Analysis
- The global actinic keratosis treatment market is fairly competitive. Business expansion through acquisitions, collaborations, partnerships, and expanding distributor network are the key strategies pursued by major participants in the actinic keratosis treatment market.
- Market leaders such as Anika Therapeutics, Inc., Hugel, Inc., Mentor Corporation, Horizon Pharma, and Gordon Laboratories contributed about 32.1% revenue share in the market in 2018.
- The global for actinic keratosis treatment market is highly consolidated for photodynamic therapy with top two brands such as Metvix from Nestle Skin Health and Levulan Kerastick from Sun Pharmaceutical, which is estimated to account for 88.1% market share.
- For a greater hold in the target market, actinic keratosis treatment market leaders are continuously emphasizing on strategies such as mergers and acquisitions. For instance, in August 2018, Leo Pharma completed the acquisition of Bayer AG’s global prescription dermatology portfolio. This agreement enabled Leo Pharma to expand its key markets worldwide and broaden its therapeutic areas.
Topical Treatment and Procedural Modality Preferred for Multiple Actinic Keratoses Treatment
Topical treatments and procedural modality account for more than three-fourth revenue share in the actinic keratosis treatment market. Whereas, the adoption of photodynamic therapy will increase at a significant CAGR over the next decade. Topical creams containing fluorouracil, which is a chemotherapy drug, and other medications such as diclofenac which is a analgesics and Imiquimod (INN) gels, are commonly prescribed in case of multiple actinic keratoses. The combination therapy of fluorouracil and cryotherapy with the help of dermatological cryosurgery units is also implemented owing to its high success rate in treating actinic keratosis.
Adoption Rate Remains Higher in Developed Regions
Actinic keratosis is one of the most commonly diagnosed skin disease in developed countries such as the U.S., Australia, and some of European countries, including Germany, France, and the U.K. An increasing number of stakeholders in the actinic keratosis treatment market are thus eying profits in these countries so as to tap their lucrative growth potential. Furthermore, despite the cost of actinic keratosis treatments being high in North America and Europe, high healthcare spending pattern would continue to create profitable opportunities for market players in these regions.
* This data is only a representation. Actual data may vary and will be available in report.
Rise in Incidence of Clinical Actinic Keratosis Influence Winning Strategies
While the prevalence of actinic keratosis is increasing across the population in most developed countries, awareness about the risk of disease progression towards the development of a cancer is compelling dermatologists for more clinical investigations. This has further pushed the diagnostic statistics vis-à-vis clinical actinic keratosis, consequently influencing the clinicians’ choice of treatment for the condition. Leading players in the actinic keratosis treatment market are noticing the change in epidemiology of clinical actinic keratosis by conducting trials to assess the efficacy of various combinations of treatments for clinical actinic keratosis lesions. Growing awareness about the severity of clinical actinic keratosis lesions will hold a significant impact on emerging trends and stakeholders’ strategies.
Procedural modality remains preferred treatment
Adoption of photodynamic therapy to gain momentum
Diagnosis of clinical actinic keratosis to shape key market trends
Prevalence of subclinical actinic keratosis remains negligible
Hospitals remain target end user
Cancer treatment centers to create high demand
How Growth will Unfold
Actinic keratosis is prominently one of most frequently observed premalignant skin diseases in the white population of the US and the EU. The elderly, fair-skinned, and immunocompromised individuals in the U.S. are highly vulnerable, as prevalence of clinical actinic keratoses is significantly high in the country. Hospitals in the U.S. are thus focusing on apt actinic keratosis treatments to improve their clinical outcomes. However, as the disease is closely linked with skin cancer, the adoption of treatment at cancer treatment centers is also buckling significantly. Rise in prevalence of solar-induced actinic keratoses will particularly create opportunities for market participants in the U.S. and European countries.
* This data is only a representation. Actual data may vary and will be available in report.Click Here To Know How The Growth Will Unfold
Custom Market Research Services
FMI offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.
Actinic Keratosis Treatment Market Analysis 2019-2029
A recent market study published by Future Market Insights (FMI) on the actinic keratosis treatment market offers global industry analysis for 2014-2018 & opportunity assessment for 2019-2029. The report consists of a comprehensive assessment of the most important market dynamics. On conducting thorough research on the historical as well as current growth parameters of the actinic keratosis treatment market, growth prospects of the market are obtained with maximum precision. The report features unique and salient factors that may make a huge impact on the development of the actinic keratosis treatment market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in the actinic keratosis treatment market in the coming years. The report provides detailed information about the current and future growth prospects of the actinic keratosis treatment market in the most comprehensive way for better understanding of readers.
Actinic Keratosis Treatment Market Taxonomy
FMI’s study on the actinic keratosis treatment market offers information divided into four important segments- treatment category, disease type, end user, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
- Topical Treatment
- 5-Fluorouracil Cream
- Diclofenac Gel
- Imiquimod Cream
- Ingenol Mebutate Gel
- Procedural Modality
- Chemical Peels
- Photodynamic Therapy
- Clinical AK
- Subclinical AK
- Private Dermatology Clinics
- Laser Therapy Centers
- Cancer Treatment Centers
- Spas and Rejuvenation Centers
- Homecare Settings
- North America
- Latin America
- East Asia
- South Asia
- Middle East and Africa
The report commences with the executive summary of the actinic keratosis treatment market report, which includes the summary of key findings and key statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the actinic keratosis treatment market.
Readers can find detailed taxonomy and the definition of the actinic keratosis treatment market in this chapter, which helps readers understand the basic information about the actinic keratosis treatment. This section also highlights the inclusions and exclusions, which helps the reader understand the scope of the report.
This section gives information about the key trends impacting the actinic keratosis treatment market
This chapter explains the key macroeconomic factor influencing the growth of actinic keratosis treatment market over the forecast period. Along with this section highlights the drivers, restraints, and opportunity analysis for actinic keratosis market. This chapter also helps readers understand the forecast factors propelling the growth of the market.
This chapter describes the parent market analysis, disease epidemiology, treatment regimen, procedure volume of cosmetic therapies, key regulations, reimbursement scenario and payer mix analysis, actinic keratosis treatment cost by region. Parent market analysis helps the reader understand the share global actinic keratosis treatment market in the overall dermatology market. Disease epidemiology section of this chapter highlights the prevalence rate treatment rate of actinic keratosis for top countries. Treatment regime section of this chapter explains the complete patient treatment journey suffering from actinic keratosis, this section also highlights the prescription pattern and combination therapies used for the actinic keratosis treatment. Key regulation section of this chapter highlights FDA and EMA regulatory process for the approval of drugs and devices. Treatment cost by region explains helps the reader understand the cost of different treatment option for actinic keratosis in the respective region.
This section explains the global market value analysis and forecast for the actinic keratosis treatment market during the forecast periods of 2019-2029. Along with the historical market and opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2019), and an incremental $ opportunity for the forecast period (2019–2029).
This chapter explains how the actinic keratosis treatment market will grow across various geographic regions, such as North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa (MEA).
Based on the treatment category, the actinic keratosis treatment market is segmented into topical treatment, procedural modality, photodynamic therapy, and others. In this chapter, readers can find information about a detailed analysis of the market by different treatment type and their growth over the forecast period.
Based on the disease, the actinic keratosis treatment market is segmented as Clinical AK and Subclinical AK. This section helps the reader to the penetration of both disease type in the market over the forecast period.
Based on the end user, the actinic keratosis treatment market is segmented into hospitals, private dermatology clinics, laser therapy centers, cancer treatment centers, spas and rejuvenation centers, and homecare settings. In this chapter, readers can find information market attractive analysis based on the end user.
This chapter includes a detailed analysis of the growth of the North America actinic keratosis treatment market along with the country-wise assessment including the U.S. and Canada. Readers can also find key takeaways of this region, and market growth based on treatment type, disease type, end-user and country of actinic keratosis treatment in the North American region.
Readers snapshot of Latin America actinic keratosis treatment market in this chapter. This chapter includes the growth prospects of the actinic keratosis treatment market in leading countries such as Brazil, Mexico, Argentina and the rest of the Latin America region.
Important growth prospects of the actinic keratosis treatment market based on its treatment category, disease type, and end user in several European countries such as the U.K., Germany, France, Italy, Spain, Russia and Rest of Europe are included in this chapter.
This chapter highlights the market growth of actinic keratosis market in South Asia by focusing on India, Thailand, Indonesia, Malaysia, and Rest of South Asia. This section also helps the reader understand key factors responsible for growth of the actinic keratosis market in South Asia.
China, Japan, South Korea are the leading countries in the East Asia region that are the prime subject of assessment to obtain growth prospects of the East Asia actinic keratosis treatment market in this chapter. Readers can find thorough information about the growth parameters of the East Asia actinic keratosis treatment market during the period 2019-2029.
Readers can find important factors that can make a huge impact on growth of the actinic keratosis treatment market in Oceania focusing on Australia and New Zealand based on the market segmentation, during the forecast period. This chapter provides the highlights of the key factor impacting the growth of Oceania actinic keratosis treatment market over.
This chapter provides information on how the actinic keratosis treatment market will grow in the major countries in MEA region, such as GCC Countries, Turkey, Northern Africa, South Africa, and Rest of MEA during the period 2019-2029.
This section highlights the growth prospects of the actinic keratosis treatment market for the emerging countries such as China, India, and Thailand.
This section explains the tier structure for global actinic keratosis treatment market, which helps the reader to understand the per cent share of market cover by tier 1, tier 2, and tier 3 players in the actinic keratosis treatment market. This section also explains the detailed analysis of market concentration and market presence by the regional footprint of players, brand share analysis for photodynamic therapy, which helps the reader understand the market share taken by key brands available in the market for photodynamic therapy.
In this chapter, readers can find a comprehensive list of all the leading manufacturer in the actinic keratosis treatment market along with detailed information about each company, including company overview, revenue shares, strategic overview, and recent company developments and SWOT analysis. Market players featured in the report include Sun Pharmaceutical Industries Ltd., Nestle Skin Health Company, Biofrontera AG, Bausch Health Companies Inc., Novartis AG, GlaxoSmithKline Plc., Leo Pharma A/S, Almirall, LLC, Cipher Pharmaceuticals Inc., and Laboratoires Pierre Fabre.
This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the report.
This chapter helps readers understand the research methodology followed to obtain various conclusions, important qualitative information, and quantitative information about the actinic keratosis treatment market.
How the research was conducted?
- C - Level Executives
- Marketing Directors
- Product Managers
- Business Development Officers
- Production Managers
- Procurement Heads
- Sales Executives
- Raw Material Suppliers
- Industry Experts
- End Users
- Current Market Dynamics and Challenges
- Yesteryear Trends
- Market Characteristics
- Market Performance and Growth Quadrants
- Competition Structure and Market Structure
- Strategic Growth Initiatives
- Near-term and Long-term Market Growth Prospects
- Market Segment Splits and Authenticity
- Opinions on Market Projections and Validity of Assumptions
- Industry Publications
- World Health Organizations (WHO)
- National Institute of Health (NIH)
- American Academy of Dermatology
- Australasian College of Dermatologists
- Dermatology Associations
- International Society of Plastic Surgery (ISAPS)
- European Medicines Agency (EMA)
- European Commission
- Medicare/Medicaid Claims
- Company Press Releases
- Annual Reports and Investor Presentations
- Research Papers
- Government Websites and Publications
- Company Websites,
Primary Interview Splits